E670G polymorphism of PCSK9 gene of patients with coronary heart disease among Han population in Hainan and three provinces in the northeast of China

Asian Pacific Journal of Tropical Medicine

Volumn 9, Issue 2, 2016, Pages 172-176

  He, Xi Min ^a   Chen, Lin ^a   Wang, Tian Song ^a   Zhang, Yun Bo ^a   Luo, Jiang Bin ^a   Feng, Xu Xia ^a  

^a Department of Internal Neurology Sanya People s Hospital   (China)

Author keywords

Coronary heart disease; E670G polymorphism; Han population; PCSK9 gene; Regional difference

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALLELE; ARTICLE; CHINA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HAN CHINESE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PCSK9 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84959909125     PISSN: 19957645     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apjtm.2016.01.008     Document Type: Article

References (16)

1. Lambert G., Sjouke B., Choque B., Kastelein J.J., Hovingh G.K. The PCSK9 decade. J Lipid Res 2012, 53(12):2515-2524.
2. Schulz R., Schlüter K.D., Laufs U. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol 2015, 110(2):4.
3. Zambrano T., Hirata M.H., Cerda Á., Dorea E.L., Pinto G.A., Gusukuma M.C., et al. Impact of 3' UTR genetic variants in PCSK9 and LDLR genes on plasma lipid traits and response to atorvastatin in Brazilian subjects: a pilot study. Int J Clin Exp Med 2015, 8(4):5978-5988.
4. Zeng J., Liu Y., Zeng Z., Chen Y.C. Study on association between polymorphismsinpcsk9 gene and coronary heart disease. J Mod Med Health 2011, 27(12):3202-3205.
5. Timms K.M., Wagner S., Samuels M.E., Forbey K., Goldfine H., Jammulapati S., et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004, 114(4):349-353.
6. Kotowski I.K., Pertsemlidis A., Luke A., Cooper R.S., Vega G.L., Cohen J.C., et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 2006, 78(3):410-422.
7. Miyake Y., Kimura R., Kokubo Y., Okayama A., Tomoike H., Yamamura T., et al. Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis 2008, 196(1):29-36.
8. Bergeron N., Phan B.A., Ding Y., Fong A., Krauss R.M. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation 2015, 132(17):1648-1666.
9. Chen S.N., Ballantyne C.M., Gotto A.M., Tan Y., Willerson J.T., Marian A.J. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol 2005, 45(10):1611-1619.
10. Zhang N. The correlation study between E670G polymorphism of PCSK9 gene as well as atorvastatin calcium and curative effect of lipid regulation on coronary artery disease 2014, [Thesis], Tianjin Medical University, Tianjin.
11. Qiu Y. Study on the association of PCSK9 polymorphim and its serum level with coronary heart disease 2011, [Thesis], University of South China, Hunan.
12. Aung L.H., Yin R.X., Miao L., Hu X.J., Yan T.T., Cao X.L., et al. The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. Lipids Health Dis 2011, 10:5.
13. Aung L.H., Yin R.X., Wu D.F., Cao X.L., Hu X.J., Miao L. Proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism interacts with alcohol consumption to modulate serum lipid levels. Int J Med Sci 2013, 10(2):124-132.
14. Cohen J.C. Emerging LDL therapies: using human genetics to discover new therapeutic targets for plasma lipids. J Clin Lipidol 2013, 7(Suppl 3):S1-S5.
15. Sayols-Baixeras S., Lluís-Ganella C., Lucas G., Elosua R. Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants. Appl Clin Genet 2014, 7:15-32.
16. Ferri N. Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases. Scientifica (Cairo) 2012 2012.